Global Venous Thromboembolism Therapeutics Market 2017-2021

Overview of the venous thromboembolism (VTE) therapeutics market

According to the market research analysts at Technavio, the global venous thromboembolism (VTE) therapeutics market is anticipated to witness impressive growth and post a CAGR of close to 7% over the forecast period. With the increase in surgical procedures such as hip and knee replacements, the market for VTE therapeutics is anticipated to have a positive outlook over the coming years. Joint replacement surgeries often result in long periods of immobility, increasing chances of developing deep vein thrombosis due to reduced blood flow. Moreover, according to the Center for Disease Control and Prevention, several cases or percutaneous coronary interventions, stent grafts, and coronary artery bypass grafting are performed each year, leading to increasing chances of developing thromboembolic events. This is also expected to boost the adoption of VTE therapeutics over the coming four years.

Patient assistance programs for VTE therapeutics, particularly for anticoagulants is an important trend gaining significant traction in the market. The vendors in the market are providing co-pay assistance to patients who are purchasing the indicated medications for VTE, for instance, Daiichi Sankyo’s drug Savaysa has an assistance program to provide financial assistance to those consuming the drug. Similarly, BMS provides support to patients buying its drugs through the Bristol-Myers Squibb Patient Assistance Foundation. With such assistance programs offered by pharmaceutical companies, the majority of patients feel inclined toward purchasing branded therapies, which will, in turn, propel this market’s growth prospects during the predicted period.

Competitive landscape and key vendors

The global VTE therapeutics market is dominated by a few key vendors including Bayer, BMS, and Sanofi. The vendors in the market are devising effective marketing strategies to remain competitive in the market. The vendors compete on the basis of price, quality, and branding.

Key vendors in this market are -

• Bayer HealthCare
• BMS
• Boehringer Ingelheim
• Daiichi Sankyo
• Johnson & Johnson
• Sanofi

Other prominent vendors in the market include Altor Bioscience, Armetheon, Aspen Pharma, BioInvent International, eXIthera Pharmaceuticals, Gamma Therapeutics, GlycoMimetics, Green Cross, Isis Pharmaceutical, Leo Pharma, Pfizer, Portola Pharmaceuticals, and ThromboGenics.

Segmentation by drug class and analysis of the VTE therapeutics market

• Factor Xa inhibitors
• Direct thrombin inhibitors
• Heparin
• Vitamin K antagonists

In terms of revenue, the Factor Xa inhibitors segment dominated the global VTE therapeutics market during 2016 and will continue to lead the market over the next four years. Factor Xa inhibitors prevent the formation of thrombin, inhibiting the formation of clots. The market for Factor Xa inhibitor drugs is growing at a fast pace owing to the approval of novel oral anticoagulants (NOACs) such as rivaroxaban (Xarelto), edoxaban (Savaysa), and apixaban (Eliquis). Moreover, the direct Factor Xa inhibitor drugs show better safety and efficacy profiles compared to conventional drugs such as heparin, which will lead to their augmented adoption until the end of 2021.

Geographical segmentation and analysis of the VTE therapeutics market

• Americas
• APAC
• EMEA

In terms of geography, the Americas was leading the global VTE therapeutics market during 2016 and will continue to dominate the market in the future. The introduction of NOACs such as Warfarin is one of the primary factors driving this market’s growth in the region. However, the recent trends observed in the market indicate that the shares of vitamin K antagonists are being taken over by Factor Xa inhibitors and direct thrombin inhibitors. The increased specificity and efficacy of Factor Xa inhibitors and direct thrombin inhibitors has fuelled its adoption rates in the region.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global VTE therapeutics market?
• What are the key market trends impacting the growth of the global VTE therapeutics market?
• What are the challenges to market growth?
• Who are the key vendors in the global VTE therapeutics market?
• What are the market opportunities and threats faced by the vendors in the global VTE therapeutics market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global VTE therapeutics market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Diabetic Therapeutic Market 2017-2021
• Global Critical Care Therapeutics Market 2017-2021
• Global Protein Therapeutics Market 2017-2021